Dublin People
  • Contact Us
  • Advertising Guidelines
  • Place a Classifieds Ad
  • Place a Memorial Ad
  • Place a Planning Ad
Toggle Menu
  • News
    • Southside
    • Northside East
    • Northside West
  • Sport
  • Lifestyle
    • Fashion & Beauty
    • Health
    • Motoring
    • Travel
    • Arts & Culture
    • House & Home
  • Community
    • Crime & Courts
  • Business
    • Education
    • Jobs
  • Digital edition
    • Northside People East edition
    • Northside West edition
    • Southside People edition
  • Competitions
  • Video
  • Contact Us
  • Advertising Guidelines
  • Place a Classifieds Ad
  • Place a Memorial Ad
  • Place a Planning Ad

Cancer breakthrough following drug trial at Tallaght University Hospital

Gary Ibbotson 01 Mar 2023

Medical researchers at Tallaght University Hospital (TUH) have taken part in a ground-breaking Clinical Trial which has discovered that the drug Rucaparib is successful in the treatment of certain prostate cancers.

The trial which began in TUH in 2017, was called TRITON 3.

The purpose of the study was to determine how patients with prostate cancer (which had spread) responded to treatment with the drug Rucaparib versus treatment with other drugs (such as Abiraterone Acetate, Enzalutamide or Docetaxel).

The trial only involved men who had either a BRCA or ATM gene mutation.

A spokesperson said that “all of the patients who took part in this study also had what is known as castrate-resistant prostate cancer.

“In short, this means that prostate cancer keeps growing even when the amount of testosterone in the body is reduced to very low levels.

Over a 5 year period, TUH screened 120 men for this study.

Patients were then asked if they would like to participate in this trial.

Once consent was given, a blood sample was shipped to Foundation Medicine in the USA.

Here, the blood was tested for a panel of genes. If the patient sample was positive for certain genes they were contacted and asked if they would like to participate in the trial.

They were then randomised to receive the study drug Rucaparib.

Advertisement

Clinical Professor of Medical Oncology at TUH, Ray Mc Dermott was one of the principal investigators for this TRITON 3 Trial.

Professor McDermott is the National Cancer ControI Programme lead in guideline development for prostate cancer.

He was also the second highest recruiter globally for the TRITON 3 trial and supervised care to the men taking part in this important new research which was partly carried out in Ireland to find better treatments for prostate cancer.

Overall, 17 patients (13 of these in TUH) had the required genes and met all other eligibility criteria and proceeded to the main trial.

Patients were reviewed regularly by the Oncology Clinical Trials team in TUH and all scans were reported by Prof William Torreggiani, Consultant Radiologist.

The drugs were supplied via the TUH pharmacy department.

“The highly regarded New England Journal of Medicine has just reported that the TRITON 3 Trial demonstrated that progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with Rucaparib versus other medications,” a spokesperson said.

“It also discovered that Rucaparib provides a potential treatment option for eligible men, with earlier-stage disease.”

The results have just been released in San Francisco at a conference organised by the American Society of Clinical Oncology which focused on genitourinary cancers.

  • Southside

Post navigation

>
<

Related News

Caught driving a van containing €780,000 worth of cannabis

Padraig Conlon • 24 Mar 23

Man jailed for eight years after Gardaí found over €2.2 million worth drugs in garage

Gary Ibbotson • 24 Mar 23

Man jailed for five years for transporting money for organised crime

Gary Ibbotson • 24 Mar 23
  • FOLLOW
    DUBLIN PEOPLE
  • Facebook
  • Twitter
  • YouTube

Trending Now

  • Local St Patrick’s Day Parades return
  • Loyle Carner at Vicar Street: Young rapper on the verge of superstardom
  • Cancer breakthrough following drug trial at Tallaght University Hospital
  • Dublin remembers Brendan Behan


Dublin People Group
Dublin People Northside East
Dublin People Northside West
Dublin People Southside

The Dublin People Group is the largest local newspaper in Dublin, with three popular weekly titles serving the city: Northside People East, Northside People West & Southside People. Each of our titles are compact and available every Monday. Our publications are distributed throughout Dublin’s suburbs to homes, pick-up points and businesses.

DPG Publications Ltd
Unit 3 Robinhood Industrial Estate Dublin 22 Ireland.
Publisher of the following newspaper titles. The Northside People East, The Northside People West & The Southside People Newspapers

  • FOLLOW
    DUBLIN PEOPLE
  • Facebook
  • Twitter
  • YouTube

Phone: 01-8621611
Advertising: sales@dublinpeople.com
News: news@dublinpeople.com
Planning: planning@dublinpeople.com

  • Contact Us
  • Cookie policy (EU)
  • Privacy statement (EU)
  • Disclaimer
  • Return,Refund and Cancellation policy
  • Advertising and Pricing Policy
Copyright © 2021 Dublin People
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}
Go to mobile version